Reported Reactions

Devices › Sensor, glucose, invasive

Device brand name · Continuous glucose monitor

Dexcom G5 Mobile Continuous Monitoring System: medical device reports filed with FDA

228 reports name it, 2016–2017. Manufacturer given most often on reports: Dexcom. Product code MDS.

228
device reports naming the brand
0% of all MAUDE reports · about 22 a year
0
reports, 12 months to August 2026
0 in the 12 months before
98.7%
classified as malfunction
94.9% across the product code
0%
classified as death, as reported
0 reports · not verified by FDA

228 medical device reports received by FDA name the brand "Dexcom G5 Mobile Continuous Monitoring System" (continuous glucose monitor); the manufacturer given most often on reports is Dexcom; received from January 2016 to May 2017. Brand names are as the reporter or manufacturer wrote them, so one product can appear under several spellings.

0 reports arrived in the 12 months to August 2026, and none in the 12 months before. FDA releases MAUDE data monthly; reports can arrive months after an event, so the newest months grow in later releases. The event types recorded are malfunction (98.7%) and injury (1.3%); across all sensor, glucose, invasive reports (product code MDS) death is recorded in 0.1% and malfunction in 94.9%. Event type is the reporter's classification of the report, not a verified outcome.

The device problems coded most often are low battery (57.5%), failure to power up (21.1%) and device operates differently than expected (4.4%). The patient problems coded most often are reaction, scarring and foreign body in patient. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data."

Reports by month, five years

No report naming Dexcom G5 Mobile Continuous Monitoring System was received in the five years to August 2026; the latest was received in May 2017.

Event type and report source

Event type, as classified on the report

Death0%0
Injury1.3%3
Malfunction98.7%225
Other0%0
Not given0%0

Who filed the report

Manufacturer report100%228
Voluntary report0%0
User facility report0%0
Distributor report0%0
Not given0%0

Grey bar: all 282,102 reports carrying product code MDS. Event type is the filer's classification and is not verified by FDA.

Device problems coded

Device problem (FDA code)ReportsShareShare across product code
Low battery13157.5%0.1%
Failure to power up4821.1%0.2%
Device operates differently than expectedthe device behaved unexpectedly104.4%28.7%
Defective alarm83.5%2.5%
Failure to sense73.1%0%
No display/image73.1%0.4%
Failure to charge62.6%0%
Wireless communication problema wireless connection problem52.2%21.3%
Device displays incorrect message20.9%20.4%
Charging problem10.4%0%
Detachment of device component10.4%1.1%
Device inoperablethe device could not be used10.4%1.1%
Display or visual feedback problem10.4%0.6%
Overheating of device10.4%0.1%
Vibration10.4%0%

FDA's device problem codes as entered on the report; one report can carry several. Generic codes such as "no apparent adverse event" are left out.

Patient problems coded

Patient problem (FDA code)ReportsShare
Reactiona reaction, type not specified20.9%
Scarring20.9%
Foreign body in patientpart of a device left in the patient10.4%

Patient problem codes are present mainly in reports filed since 2019 and are often blank.

In context

MeasureDexcom G5 Mobile Continuous Monitoring SystemProduct code MDSAll MAUDE reports
Reports228282,10226,136,888
Share of that pool—0.1%0%
Classified as death, per 1,000 reports019
Classified as injury1.3%4.8%36.2%
Classified as malfunction98.7%94.9%62.3%
Filed by the manufacturer100%99.6%94.9%

Shares are of reports, not of devices in use. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data."

Other brands with product code MDS

BrandReportsLatest 12 monthsClassified as death
Dexcom G5 Mobile Continuous Glucose Monitoring System332,49260%
Dexcom G4 Platinum Continuous Glucose Monitoring System53,68100.1%
G4 Platinum Continuous Glucose Monitoring System48,90600.1%
Dexcom G4 Platinum Continuous Glucose Monitoring System Dexcom Share System17,71700.1%
Xmtr MMT-7811NA GST3C Lockout17,012650%
Animas Vibe88,70300%
Paradigm Real-Time Insulin Infusion Pump126,28200.3%
Unknown XMTR4,4312,0270%
Carelink Personal Mmt-73333,6802330%
Guardian Link 3 OUS6,6637330%
Ni32,9391,5871.8%
Dexcom G4 Platinum Continuous Monitoring System Dexcom Share System2,29300.3%
Paradigm Real-Time Revel Insulin Infusion Pump178,69100.6%
Transmitter Mmt-7841zw Gst5g Ous31,57212,3510%
Xmtr Mmt-7821lna Gst4c Replacement1,685130%

Ordered by report count for navigation only. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data." FDA also states that "common products may have a higher number of adverse events due to the higher total number of people using the product."

Questions about Dexcom G5 Mobile Continuous Monitoring System reports

How many FDA reports name Dexcom G5 Mobile Continuous Monitoring System?

228 medical device reports in the openFDA MAUDE release of 28 Sep 2026, covering reports received through August 2026; 0 in the latest 12 months.

What kinds of events are reported?

malfunction (98.7%) and injury (1.3%). "Event type" is how the report was classified when filed: death, injury, malfunction or other.

What device problems are coded?

low battery (57.5%), failure to power up (21.1%), device operates differently than expected (4.4%), defective alarm (3.5%) and failure to sense (3.1%). These are FDA's device problem codes as entered on the report.

Who files these reports?

manufacturer reports (100%). Manufacturers and user facilities are required to report; voluntary reports come from health professionals and the public.

Do these reports show that Dexcom G5 Mobile Continuous Monitoring System was at fault?

No. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data." FDA adds that "a causal relationship cannot be established between product and reactions listed in a report."

How do I report a problem with a medical device?

Through FDA MedWatch (Form FDA 3500 for health professionals and consumers), or to the manufacturer. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Device Adverse Event (MAUDE) bulk export released 28 Sep 2026, which holds reports FDA received through 31 Aug 2026. Brand, generic and manufacturer names are as written on the reports; product code names come from FDA's device classification. A report counts here when any device it lists carries this brand name after punctuation and capitalisation are normalised. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.